Immunogenicity and safety of influenza vaccine in lung cancer patients receiving immune checkpoint inhibitors

Immunogenicity and safety of influenza vaccine in lung cancer patients receiving immune checkpoint inhibitors - Immunogenicity and safety of influenza vaccine in lung cancer patients receiving immune checkpoint inhibitors

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041923

Enrollment

Registered

2020-09-28

Start date

2020-09-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

influenza

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 Lung cancer patients aged 50 years or older receiving immune checkpoint inhibitors And 2 Who receive influenza vaccine at their own will and have voluntarily agreed to participate in this study

Exclusion criteria

Exclusion criteria: 1 Patients who have been vaccinated with influenza vaccine in the 2020/2021 season 2 Patients who have had anaphylaxis due to the components of influenza vaccine, or those who may have allergies 3 Patients with egg allergies 4 Influenza infected patients in 2020/2021 season 5 Patients who suffered from acute febrile illness or other serious illness at the timing of vaccination 6 Those who received a cytotoxic agent within 1 month of vaccination 7 Those who are taking steroids / immunosuppressants (excluding administration as antiemetics) 8 Others who are not suitable for vaccination

Design outcomes

Primary

Measure	Time frame
seroprotection rate 3 to 5 weeks after the vaccination	—

Secondary

Measure	Time frame
geometric mean titer before and 3 to 5 weeks after the vaccination mean fold rises, seroresponse rate, seroconversion rate 3 to 5 weeks after the vaccination presence of immune-related adverse events within 6 months of the vaccination	—

Countries

Japan

Contacts

Public ContactKei Nakashima

Kameda Medical Center Department of Pulmonology

kei.7.nakashima@gmail.com04-7092-2211

Outcome results